Sonnet BioTherapeutics Holdings, Inc. short interest in 2020
In 2020, Sonnet BioTherapeutics Holdings, Inc.'s disclosed short interest ran from 0.48% of shares outstanding on 15 Jan 2020 to 4.83% on 31 Dec 2020, a change of +4.35 percentage points. The year's high was 10.79% on 30 Sep 2020 and its low 0.31% on 31 Jan 2020, averaging 6.44% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.59 days on 30 Oct 2020. Full history: Sonnet BioTherapeutics Holdings, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
2020 in figures
- Start of year
- 0.48% (15 Jan 2020)
- End of year
- 4.83% (31 Dec 2020)
- Change
- +4.35 pp
- High
- 10.79% (30 Sep 2020)
- Low
- 0.31% (31 Jan 2020)
- Average
- 6.44%
- Highest days to cover
- 4.59 (30 Oct 2020)
- SEC filings marked
- 7
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 0.48% | 1.38 | |
| 31 Jan 2020 | 0.31% | 1.00 | |
| 14 Feb 2020 | 0.31% | 1.00 | |
| 31 Mar 2020 | 8.61% | 1.00 | 10-K filed |
| 15 Jul 2020 | 4.49% | 2.80 | 10-Q filed, results (8-K) |
| 31 Jul 2020 | 4.51% | 1.00 | |
| 14 Aug 2020 | 6.07% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2020 | 7.60% | 1.00 | |
| 15 Sep 2020 | 10.43% | 1.82 | |
| 30 Sep 2020 | 10.79% | 2.02 | |
| 15 Oct 2020 | 10.24% | 2.19 | |
| 30 Oct 2020 | 9.41% | 4.59 | |
| 13 Nov 2020 | 9.05% | 3.59 | |
| 30 Nov 2020 | 10.36% | 1.72 | |
| 15 Dec 2020 | 5.59% | 1.00 | |
| 31 Dec 2020 | 4.83% | 1.25 | 10-K filed, results (8-K) |
See also: Sonnet BioTherapeutics Holdings, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.